CARMIL2

Across TCGA pan-cancer cohorts, CARMIL2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CARMIL2 data layer compared with 29 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher CARMIL2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated CARMIL2 expression acts as an unfavorable survival marker, although some lineages such as LUAD and PDAC show a favorable association.

LUAD, PDAC, and HNSC are the cancer types where CARMIL2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Tertile	All	0.846	0.454	<.001	44	view →
PDAC	DFS	Median	All	0.886	0.629	.006	43	view →
HNSC	DFS	Median	III,IV	1.000	0.900	.009	18	view →
GBM	DFS	Quartile	All	0.832	0.621	.033	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CARMIL2–LUAD (DFS)

Open the LUAD breakdown →